Lynn Anne Bristol

Array ( [id] => 17369991 [patent_doc_number] => 20220025043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/378030 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378030 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272023 [patent_doc_number] => 12441792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof [patent_app_type] => utility [patent_app_number] => 17/378050 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 36 [patent_no_of_words] => 32235 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369990 [patent_doc_number] => 20220025042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/377924 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377924 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704636 [patent_doc_number] => 20220204642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/376627 [patent_app_country] => US [patent_app_date] => 2021-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18051627 [patent_doc_number] => 11524998 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-13 [patent_title] => Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules [patent_app_type] => utility [patent_app_number] => 17/375860 [patent_app_country] => US [patent_app_date] => 2021-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 61 [patent_no_of_words] => 84756 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17375860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356807 [patent_doc_number] => 20220017603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHOD FOR ISOLATION OF SOLUBLE POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/372966 [patent_app_country] => US [patent_app_date] => 2021-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17372966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399666 [patent_doc_number] => 20220041756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => CYTOTOXICITY-INDUCING THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 17/367909 [patent_app_country] => US [patent_app_date] => 2021-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17367909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18628286 [patent_doc_number] => 20230287143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => BINDING PROTEIN IN FAB-HCAB STRUCTURE [patent_app_type] => utility [patent_app_number] => 18/013530 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18013530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256143 [patent_doc_number] => 12428486 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides [patent_app_type] => utility [patent_app_number] => 17/353648 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 39 [patent_no_of_words] => 132717 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17353648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20179503 [patent_doc_number] => 20250263461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => RECOMBINANT T-CELL RECEPTORS THAT BIND THE NY-ESO-1 AND/OR LAGE-1A CANCER ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/250347 [patent_app_country] => US [patent_app_date] => 2021-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109606 [patent_doc_number] => 20230002486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => BISPECIFIC ANTIBODIES TARGETING HUMAN CLAUDIN 18.2 AND PROGRAMMED DEATH-LIGAND 1 (PD-L1) [patent_app_type] => utility [patent_app_number] => 17/350525 [patent_app_country] => US [patent_app_date] => 2021-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17350525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156390 [patent_doc_number] => 20210317441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES [patent_app_type] => utility [patent_app_number] => 17/343905 [patent_app_country] => US [patent_app_date] => 2021-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855596 [patent_doc_number] => 12258420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Engineered IGA antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/343249 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 59 [patent_no_of_words] => 80342 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17641975 [patent_doc_number] => 20220169713 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHODS FOR TREATING OSTEOARTHRITIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 17/339442 [patent_app_country] => US [patent_app_date] => 2021-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18485003 [patent_doc_number] => 20230212321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES [patent_app_type] => utility [patent_app_number] => 17/926283 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18657761 [patent_doc_number] => 20230303715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS [patent_app_type] => utility [patent_app_number] => 17/999477 [patent_app_country] => US [patent_app_date] => 2021-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19909305 [patent_doc_number] => 12285493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-29 [patent_title] => Polypeptides antagonizing Wnt signaling in tumor cells [patent_app_type] => utility [patent_app_number] => 17/316042 [patent_app_country] => US [patent_app_date] => 2021-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 20 [patent_no_of_words] => 22953 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17316042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421303 [patent_doc_number] => 11254745 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-02-22 [patent_title] => Anti-CD4 antibodies [patent_app_type] => utility [patent_app_number] => 17/315343 [patent_app_country] => US [patent_app_date] => 2021-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 25023 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 414 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19274458 [patent_doc_number] => 12024569 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => HER2/neu-specific antibodies and methods of using same [patent_app_type] => utility [patent_app_number] => 17/308356 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 29230 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036749 [patent_doc_number] => 20210253707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => GM-CSF/CD40L VACCINE AND CHECKPOINT INHIBITOR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/246917 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246917 [rel_patent_id] =>[rel_patent_doc_number] =>)